Davide Rossi

This study identifies IL-16 production as a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas, showing that targeting the IL-16/CD9 axis restores drug sensitivity.

The paper shows ibrutinib increases CD19 expression in B-cell lymphoma models, improving the effectiveness of CD19-CAR T cells.

This paper shows that CDK9 inhibitor PRT2527 kills marginal zone lymphoma cells, even those resistant to other drugs, and enhances the effects of BTK, PI3K, and BCL2 inhibitors.

This study evaluates the preclinical efficacy of BGB-16673 and sonrotoclax in marginal zone lymphoma models, showing enhanced apoptosis when combined.

This study identifies PLK1 inhibition as a strategy to enhance BTK blockade in MZL by overcoming resistance through transcriptomic and mechanistic analysis.

This study shows that combining CXCR4 inhibitors with standard and targeted therapies improves anti-tumor effects in B-cell lymphoma models, especially in drug-resistant cases.

This paper identifies two resistance mechanisms to the CD37-targeting ADC naratuximab emtansine in lymphoma cell lines and suggests combination therapies to overcome resistance.

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

The paper identifies genomic and transcriptomic changes in CLL transforming to RS, finding pathway mutations and non-coding mutations in PAX5 enhancers associated with transformation.